Category Internal Medicine

Alatrofloxacin and trovafloxacin

See also Fluoroquinolones General information Alatrofloxacin is a fluoronaphthyridone that is hydrolysed to the active moiety, trovafloxacin, after intravenous administration. This fourth-generation broad-spectrum fluoroquinolone has activity against Gram-positive, Gram-negative, anerobic, and atypical respiratory pathogens. Because it has significant hepatotoxicity, the…

Ajmaline and its derivatives

General information Ajmaline and its derivatives, prajmalium bitartrate (rINN; N-propylajmaline), lorajmine (rINN; chloroacetylajmaline), detajmium bitartrate (rINN), and diethylaminohydroxypropylajmaline, are Rauwolfia alkaloids. Their use is restricted by serious adverse effects, such as neutropenia and cardiac dysrhythmias, which have been reviewed […

Adrenoceptor agonists

General information Subtypes of adrenoceptors were first described by Ahlquist in 1948 [ , ]. Adrenoceptor agonists evoke physiological responses similar to those produced by stimulation of adrenergic nerves or the physiological release of adrenaline (see Table 1 ). For…

Adrenaline (Epinephrine)

See also Adrenoceptor agonists General information Note on nomenclature Although “epinephrine” is the recommended International Non-proprietary Name (rINN), there are good reasons why the name “adrenaline” should be preferred, based on usage, history, etymology, and, most importantly, risk of clinical…

Ademetionine

General information Ademetionine ( S -adenosylmethionine) has anti-inflammatory and analgesic effects in animals. Convincing evidence of these effects in man is still lacking. You’re Reading a Preview Become a Clinical Tree membership for Full access and enjoy Unlimited articles Become…

Adefovir

General information Adefovir is an adenine analogue reverse transcriptase inhibitor. While it has activity against both HIV and hepatitis B, its use in HIV infection is limited by nephrotoxicity due to the high doses needed [ ]. The dose used…

Adalimumab

See also Monoclonal antibodies General information Adalimumab, a fully human monoclonal antibody, is the third commercially available TNF alfa antagonist for patients with rheumatoid arthritis for whom previous treatment with disease-modifying antirheumatic drugs has failed. Adalimumab has been approved alone…